Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide to Prevent Weight Gain Following Liver Transplantation
NCT05424003Phase 2Recruiting
- Sponsor
- University of Virginia
- Start
- Feb 2024
- Primary completion
- Aug 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in non-alcoholic fatty liver disease (NAFLD), sponsored by University of Virginia. Started Feb 2024; status: recruiting.
02
Drugs
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05424003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05424003.